Trial reportBlood2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
Trial report in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00504504 (A Phase II Study of Rituximab + ABVD for Patients With Hodgkin's Disease), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Rituximab + ABVD for Patients With Hodgkin's Disease
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Analysis of Clinical Trials Using Anti-Tumor Traditional Chinese Medicine Monomers.Drug design, development and therapy · 2024Pooled it
- The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.European journal of nuclear medicine and molecular imaging · 2022Pooled it
- Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial.Journal for immunotherapy of cancer · 2022Trial
- ABVD plus rituximabHaematologica · 2019Trial
- Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.Molecular imaging and biology · 2017Trial
- Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.European journal of nuclear medicine and molecular imaging · 2014Trial
- Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.International journal of molecular sciences · 2023Review
- Review
- Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience.Leukemia research reports · 2021Article
- Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.International journal of molecular sciences · 2019Review
- Review
- Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.British journal of haematology · 2019Review
- Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.Cancer discovery · 2017Article
- Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.Blood and lymphatic cancer : targets and therapy · 2017Article
- The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.Haematologica · 2016Review
- Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma.Radiology and oncology · 2015Review
- Targeting the tumor niche to treat cancer.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection.Haematologica · 2014Article
- The tumour microenvironment in B cell lymphomas.Nature reviews. Cancer · 2014Review
Corrections and comments
- Commented on by
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
Abstract
In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin lymphoma (cHL). In this phase 2 study, patients with chemotherapy-naive, advanced-stage cHL were treated with rituximab 375 mg/m(2) weekly for 6 weeks and standard ABVD for 6 cycles. The primary outcome was event-free survival (EFS) at 5 years. Eighty-five patients were enrolled, of whom 78 were eligible. With a median follow-up duration of 68 months (range, 26-110), and based on an intent-to-treat analysis, the 5-year EFS and overall survival rates were 83% and 96%, respectively. The 5-year EFS for patients with stage III/IV cHL was 82%. Furthermore, the 5-year EFS for patients with an International Prognostic Score of 0-2 was 88% and for those with a score of > 2, it was 73%. The most frequent treatment-related grade 3 or 4 adverse events were neutropenia (23%), fatigue (9%), and nausea (8%). Our results demonstrate that the addition of rituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL. These data are currently being confirmed in a multicenter randomized trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.